Featured Research

from universities, journals, and other organizations

Diabetes drug, liraglutide, improves risk factors for heart disease

Date:
June 23, 2014
Source:
Endocrine Society
Summary:
Treatment with the diabetes drug liraglutide, in combination with diet and exercise, led to a significant reduction in weight and improved a number of cardiovascular risk factors, including high blood pressure and high cholesterol, according to a multicenter study. The results were from more than 3,700 overweight and obese nondiabetic adults.

Treatment with the diabetes drug liraglutide, in combination with diet and exercise, led to a significant reduction in weight and improved a number of cardiovascular risk factors, including high blood pressure and high cholesterol, according to a multicenter study. The results, from more than 3,700 overweight and obese nondiabetic adults, were presented Saturday at the joint meeting of the International Society of Endocrinology and the Endocrine Society: ICE/ENDO 2014 in Chicago.

"If these improvements continue over time, they may result in a lower risk of heart disease," said the study's principal investigator, Carel Le Roux, MD, PhD, Diabetes Complications Research Centre, University College Dublin.

The drug is undergoing testing at a 3 milligram (mg) dose for long-term weight management as part of the SCALE™ (Satiety and Clinical Adiposity -- Liraglutide Evidence in Nondiabetic and Diabetic Subjects) Obesity and Prediabetes trial. Liraglutide currently is marketed as Victozaฎ in 1.2 mg and 1.8 mg injectable doses for adults with Type 2 diabetes to help control blood glucose (sugar) when used along with diet and exercise. The drug does not have approval for weight loss, according to its manufacturer, Denmark-headquartered Novo Nordisk, which sponsored the study.

The study included 3,731 nondiabetic obese adults and overweight adults who had at least one other risk factor for diabetes and heart disease, such as prediabetes, high blood pressure or high cholesterol. As part of the study's weight loss efforts, all subjects exercised and ate 500 fewer calories per day than usual. In addition, they were randomly assigned, in a 2-to-1 ratio, to a once-daily injection with either 3 mg of liraglutide (2,487 subjects) or placebo (1,244 subjects) for 56 weeks. Neither the subjects nor the investigators knew who received the active drug.

On average, individuals treated with liraglutide 3 mg lost 5.4 percent more of their body weight, achieving a total of 8 percent, and nearly 1.7 more inches (4.2 centimeters) around their waist than did those who received placebo, the investigators reported.

Compared with the placebo group, liraglutide-treated subjects also experienced better improvements in blood pressure and levels of all fasting lipids (blood fats), including LDL ("bad") cholesterol, HDL ("good") cholesterol, triglycerides and total cholesterol, according to Le Roux. These improvements, he said, resulted in a greater reduction in net use of blood pressure drugs and lipid-lowering medications in the liraglutide 3 mg group than in the placebo group.

In general, the researchers found liraglutide 3 mg to have a safety profile that was similar to that found in previous clinical trials of the drug in individuals with Type 2 diabetes treated with lower doses.

"Current obesity treatment options are limited," Le Roux said. "There is a need for new treatment options for people who struggle with obesity and obesity-related diseases that can help in reducing their weight."


Story Source:

The above story is based on materials provided by Endocrine Society. Note: Materials may be edited for content and length.


Cite This Page:

Endocrine Society. "Diabetes drug, liraglutide, improves risk factors for heart disease." ScienceDaily. ScienceDaily, 23 June 2014. <www.sciencedaily.com/releases/2014/06/140623141901.htm>.
Endocrine Society. (2014, June 23). Diabetes drug, liraglutide, improves risk factors for heart disease. ScienceDaily. Retrieved July 28, 2014 from www.sciencedaily.com/releases/2014/06/140623141901.htm
Endocrine Society. "Diabetes drug, liraglutide, improves risk factors for heart disease." ScienceDaily. www.sciencedaily.com/releases/2014/06/140623141901.htm (accessed July 28, 2014).

Share This




More Health & Medicine News

Monday, July 28, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Traditional African Dishes Teach Healthy Eating

Traditional African Dishes Teach Healthy Eating

AP (July 28, 2014) — Classes are being offered nationwide to encourage African Americans to learn about cooking fresh foods based on traditional African cuisine. The program is trying to combat obesity, heart disease and other ailments often linked to diet. (July 28) Video provided by AP
Powered by NewsLook.com
West Africa Gripped by Deadly Ebola Outbreak

West Africa Gripped by Deadly Ebola Outbreak

AFP (July 28, 2014) — The worst-ever outbreak of the deadly Ebola epidemic grips west Africa, killing hundreds. Duration: 00:48 Video provided by AFP
Powered by NewsLook.com
Trees Could Save More Than 850 Lives Each Year

Trees Could Save More Than 850 Lives Each Year

Newsy (July 27, 2014) — A national study conducted by the USDA Forest Service found that trees collectively save more than 850 lives on an annual basis. Video provided by Newsy
Powered by NewsLook.com
Google's Next Frontier: The Human Body

Google's Next Frontier: The Human Body

Newsy (July 27, 2014) — Google is collecting genetic and molecular information to paint a picture of the perfectly healthy human. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins